Genfit
Ipsen places €480m bet on Genfit’s liver drug elafibranor
Phil Taylor
elafibranor, Genfit, hepatology, Ipsen, partnering, primary biliary cholangitis
0 Comment
X
Ipsen places €480m bet on Genfit’s liver drug elafibranor
https://pharmaphorum.com/news/ipsen-places-e480m-bet-on-genfits-liver-drug-elafibranor/
Gilead pushes on with NASH partnership with Novo Nordisk
Richard Staines
Genfit, Gilead, Intercept, NASH, Novo Nordisk, semaglutide
0 Comment
X
Gilead pushes on with NASH partnership with Novo Nordisk
https://pharmaphorum.com/news/gilead-pushes-on-with-nash-partnership-with-novo-nordisk/
Genfit abandons late-stage trial of NASH drug elafibranor
Phil Taylor
clinical trial, Genfit, hepatology, NASH
0 Comment
X
Genfit abandons late-stage trial of NASH drug elafibranor
https://pharmaphorum.com/news/genfit-abandons-late-stage-trial-of-nash-drug-elafibranor/
X
Genfit’s NASH hopes are dashed by phase 3 trial fail
https://pharmaphorum.com/news/genfits-nash-hopes-are-dashed-by-phase-3-trial-fail/
Genfit encounters trial recruitment problem in hunt for NASH patients
Richard Staines
Bristol-Myers Squibb, Genfit, Intercept, NASH
0 Comment
Genfit was among a group of NASH companies publishing updates at the International Liver Congress.
X
Genfit encounters trial recruitment problem in hunt for NASH patients
https://pharmaphorum.com/news/genfit-encounters-trial-recruitment-problem-pharmas-hunt-nash-patients/